BioSpace News Archive

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Saraswathy (“Sara”) Nochur, Ph.D., to its Board of Directors.

numares announces FDA 510(k) Submission of AXINON System ® , a NMR platform for metabolomics-based, AI-driven Diagnostics

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Mark De Rosch, Ph.D. as Chief Operating Officer.

NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Intervention Insights, Inc. d/b/a Trapelo Health, an Information Technology company focused on precision oncology.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the year ended December 31, 2020 and provided a business update.

Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Catherine Friedman, a financial industry expert with nearly 40 years of financial industry experience, has been appointed to the company’s board of directors.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the United States Food and Drug Administration (FDA) granted Fast Track designation to REN001 for the treatment of patients with primary mitochondrial myopathies (PMM).

Waters Bills Would Eliminate Cost-Sharing for Insulin-Dependent Seniors and Provide Needed Grants for Diabetes Prevention, Care and Treatment

IQM Quantum Computers (IQM) announced today that Helmut Jeggle has joined IQM´s board of directors. He joins the company during a transformational phase